Company Overview and News


Add PFZ
to your dashboard

Headline News

Understanding Aducanumab's Potential In Alzheimer's

17m seekingalpha
Additional data from a Phase 1 trial on Aducanumab has been reported this summer, while the drug is in Phase 3 testing. (349-0)

Pfizer Inc. 2017 Q3 - Results - Earnings Call Slides

10h seekingalpha
The following slide deck was published by Pfizer Inc. in conjunction with their 2017 Q3 earnings call. (16-0)

Pfizer's Cancer Drug Sutent Gets FDA Nod for Label Expansion

2017-11-17 zacks
Pfizer Inc. (PFE - Free Report) announced that the FDA has approved a label expansion for its cancer drug Sutent (sunitinib malate). With this latest approval, Sutent’s label has been expanded as an adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma (“RCC”) following surgery. This approval makes it the first and only adjuvant therapy for recurrent RCC, the most common type of kidney cancer. (94-0)

Purdue Approaches States in Bid to Settle Opioid Claims - Bloomberg

2017-11-17 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (21-0)

10 Top-Rated Vanguard Funds to Buy Now

2017-11-17 investorplace
The Vanguard Group is a behemoth, with a staggering $4.4 trillion in assets under management. This puts the firm as the No. 2 player in the asset management world, just behind BlackRock, Inc. (NYSE:BLK). (157-0)

Why It’s Time to Put Pfizer Inc. Stock on Your Watchlist

2017-11-17 investorplace
Ever since its cholesterol-fighting drug Lipitor lost the crux of its patent protection back in 2011, Pfizer Inc. (NYSE:PFE) investors have approached PFE stock with caution. And, perhaps for good reason. Though the PFE stock price has almost doubled since generic versions of Lipitor were introduced (bear in mind Pfizer shares suffered plenty before the drug fell off the patent cliff), revenue only began to grow again last year. (123-0)

Pfizer (PFE) a Hold on Pallid Sales Growth

2017-11-17 investorplace
Pfizer Inc (NYSE:PFE) is a $209.7 billion in market value component of the Pharmaceuticals GICS industry group where the ranking for PFE by Portfolio Grader places it 44 among the 132 companies in this industry group, placing it in the top half. PFE is ranked in the top half of the sector with a ranking of 286 among the 782 companies in the sector and number 1,779 in the 5000 company Portfolio Grader company universe. (16-0)

Cancer Space Update: Label Expansion for Three Major Drugs

2017-11-17 zacks
With a busy earnings season almost coming to an end after an impressive run, we are again focused on latest cancer updates happening every week. The week gone by saw three cancer drugs receiving FDA approval for new indications – Roche Holding AG’s (RHHBY - Free Report) Gazyva, Pfizer Inc.’s (PFE - Free Report) Sutent and AstraZeneca PLC’s (AZN - Free Report) Faslodex. However, an interesting product in development is a cancer vaccine that Moderna Therapeutics and Merck (MRK - Free Report) are working on. (396-1)

U.S. FDA expands approval for Pfizer cancer drug Sutent

2017-11-16 reuters
Nov 16 (Reuters) - The U.S. Food and Drug Administration on Thursday approved the use of Pfizer Inc’s cancer drug Sutent to help prevent kidney cancer from returning following surgical removal of a kidney. (16-0)

What Do Versartis (NASDAQ: VSAR)'s Troubles Mean For Opko Health (NASDAQ: OPK)? | Benzinga

2017-11-16 benzinga
Versartis Inc (NASDAQ: VSAR) shares are slumping even as rival Opko Health Inc. (NASDAQ: OPK) is seeing slight strength, though not proportionate to the sell-off seen in Versartis shares. (144-2)

Despite Valeant Improvement, VRX Stock Price Is Still Too High

2017-11-15 investorplace
Give credit where credit is due. New CEO Joe Papa has done a nice job in his efforts to turn around Valeant Pharmaceuticals Intl Inc (NYSE:VRX). So far, it hasn’t done much for the VRX stock price, which is basically flat so far in 2017. But flat performance in this market actually isn’t that bad. (324-0)

Astellas faces U.S. probe over patient assistance charity support

2017-11-15 reuters
BOSTON (Reuters) - Astellas Pharma Inc has become the latest company to reveal it has become the subject of a U.S. probe into drugmakers’ financial support of charities offering assistance to Medicare patients seeking help to cover out-of-pocket drug costs. (259-0)

Astellas faces US probe over patient assistance charity support

2017-11-15 channelnewsasia
Astellas Pharma Inc has become the latest company to reveal it has become the subject of a U.S. probe into drugmakers' financial support of charities offering assistance to Medicare patients seeking help to cover out-of-pocket drug costs. (259-0)

How to Know if You Should Buy, Sell or Hold Pfizer Inc.

2017-11-14 investorplace
Every once in awhile, someone will ask me what’s a good stock to buy. That is a loaded question if there ever was one. I usually say it depends on what they hope to achieve by owning it. That’s not a cop-out. Rather, it’s a way to determine if they’re looking to hit a home run or a comfortable single. Pfizer Inc. (NYSE:PFE) and PFE stock is a good example of this. (16-0)

This Simple, Lifesaving Liquid Is Suddenly In Short Supply - Bloomberg

2017-11-14 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (53-0)